Literature DB >> 18840135

Extent of prophylactic postoperative radiotherapy after radical surgery of thoracic esophageal squamous cell carcinoma.

J-C Lu1, H Tao, Y-Q Zhang, W-W Zha, P-D Qian, F Li, K-X Xu.   

Abstract

SUMMARY: The aim of this study was to assess if the entire mediastinum (M), the bilateral supraclavicular area (S), and the left gastric area (L) should be all included in the irradiation volume. The clinical data of 204 patients with thoracic esophageal squamous cell carcinoma who had undergone prophylactic postoperative radiotherapy after radical surgery were retrospectively reviewed. They were classified into four groups: group A, 26 patients with irradiated M alone; group B, 139 patients with irradiated M + S; group C, 10 patients with irradiated M + L; and group D, 29 patients with irradiated M + S + L. The 5-year disease-free survival rates were 36% in group A, 31% in group B, 40% in group C and 44% in group D (chi2=3.05, P =0.39), respectively. Multivariate analysis revealed that the irradiated extent was not a significant influential factor (hazard ratio=0.84, 95% confidence interval, 0.69-1.03, P =0.10). None of 43 patients without the L irradiated and with disease in the upper and middle upper thirds (defined in middle third but with upper third invaded), and one of 83 patients without the L irradiated and with disease in the middle third only thoracic esophagus were shown to have abdominal lymph node metastasis. Supraclavicular lymph node metastasis in patients in the lower and middle lower thirds (defined in middle third but with lower third invaded) were, respectively, 1/43 and 1/18 whether the S was irradiated or not. It seems unnecessary that the L be irradiated when the primary site is in the upper, middle, and middle upper thirds of the thoracic esophagus after radical surgery. Similarly, S may be unnecessarily irradiated in the lower and middle lower thirds.

Entities:  

Mesh:

Year:  2008        PMID: 18840135     DOI: 10.1111/j.1442-2050.2007.00797.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  9 in total

1.  Notch-1-mediated esophageal carcinoma EC-9706 cell invasion and metastasis by inducing epithelial-mesenchymal transition through Snail.

Authors:  Tao Wang; Xiaoyan Xuan; Linping Pian; Ping Gao; Hong Hu; Yuling Zheng; Wenqiao Zang; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2014-02

2.  Stat3 promotes invasion of esophageal squamous cell carcinoma through up-regulation of MMP2.

Authors:  Xaioyan Xuan; Shanshan Li; Xi Lou; Xianzhao Zheng; Yunyun Li; Feng Wang; Yuan Gao; Hongyan Zhang; Hongliu He; Qingru Zeng
Journal:  Mol Biol Rep       Date:  2014-11-19       Impact factor: 2.316

Review 3.  Postoperative radiation in esophageal squamous cell carcinoma and target volume delineation.

Authors:  Yingming Zhu; Minghuan Li; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-07-11       Impact factor: 4.147

4.  Recurrence pattern of squamous cell carcinoma in the midthoracic esophagus: implications for the clinical target volume design of postoperative radiotherapy.

Authors:  Xiaoli Wang; Yijun Luo; Minghuan Li; Hongjiang Yan; Mingping Sun; Tingyong Fan
Journal:  Onco Targets Ther       Date:  2016-10-03       Impact factor: 4.147

5.  Exosomal lncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis.

Authors:  Zhirong Li; Xuebo Qin; Wei Bian; Yishuai Li; Baoen Shan; Zhimeng Yao; Shujun Li
Journal:  J Exp Clin Cancer Res       Date:  2019-11-27

6.  Phase II Trial of Intensity-Modulated Radiotherapy Concurrent With Chemotherapy for Postoperative Node-Positive Esophageal Squamous Cell Carcinoma.

Authors:  Hua Tao; Yiqin Zhou; Chengyun Yao; Dayong Gu; Wei Chen; Jincheng Lu
Journal:  Oncol Res       Date:  2017-03-08       Impact factor: 5.574

7.  Adjuvant Radiotherapy of Involved Field versus Elective Lymph Node in Patients with Operable Esophageal Squamous Cell Cancer: A Single Institution Prospective Randomized Controlled Study.

Authors:  Ruifeng Liu; Xueliang Zhang; Qiuning Zhang; Hongtao Luo; Shihong Wei; Tingting Liu; Shilong Sun; Zhiqiang Liu; Zheng Li; Jinhui Tian; Xiaohu Wang
Journal:  J Cancer       Date:  2021-03-31       Impact factor: 4.207

8.  Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study.

Authors:  Wei Deng; Jinsong Yang; Wenjie Ni; Chen Li; Xiao Chang; Weiming Han; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Xin Wang; Lei Deng; Wenqing Wang; Nan Bi; Tao Zhang; Yexiong Li; Shugeng Gao; Qi Xue; Yousheng Mao; Kelin Sun; Xiangyang Liu; Dekang Fang; Dali Wang; Jian Li; Jun Zhao; Kang Shao; Zhishan Li; Xinjie Chen; Lei Han; Lifang Wang; Jie He; Zefen Xiao
Journal:  Oncologist       Date:  2020-02-21

9.  Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy.

Authors:  Qi Liu; Xu-Wei Cai; Bin Wu; Zheng-Fei Zhu; Hai-Quan Chen; Xiao-Long Fu
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.